The effect of chemoprophylaxis with tamoxifen in patients with a hereditary predisposition has been extrapolated from studies examining the risk of developing contralateral breast cancer in BRCA1/2-mutation carriers who were treated with tamoxifen after their primary breast cancer diagnosis, as well as tamoxifen use in the general population. The gene discussed is BRCA1; the disease is breast cancer.